Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q1 FY20 results · Apr–Jun 2019
Solara Active Pharma Sciences reported revenue from operations of ₹330.17 crore (up 9.0% from Q1 FY19) and net profit of ₹26.50 crore (up 927.5% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 330.17 | 302.81 | +9.0% | 385.31 | −14.3% |
| Other income | 4.36 | 0.48 | +800.8% | 6.63 | −34.2% |
| Total income | 334.53 | 303.30 | +10.3% | 391.94 | −14.6% |
| Profit before tax | 26.50 | 9.26 | +186.2% | 26.16 | +1.3% |
| Net profit for the period | 26.50 | 2.58 | +927.5% | 26.20 | +1.1% |
| Attributable to shareholders of the company | 26.52 | 2.56 | +934.5% | 26.32 | +0.8% |
| EPS, basic (₹) | 10.29 | 0.23 | not comparable | 10.17 | +1.2% |
| Net margin (%) | 8.0 | 0.9 | 6.8 |
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 314.09 | 302.81 | +3.7% | 380.10 | −17.4% |
| Other income | 2.97 | 0.43 | +590.7% | 3.63 | −18.2% |
| Total income | 317.06 | 303.24 | +4.6% | 383.73 | −17.4% |
| Profit before tax | 25.32 | 9.66 | +162.1% | 28.44 | −11.0% |
| Net profit for the period | 25.32 | 2.98 | +749.7% | 27.06 | −6.4% |
| EPS, basic (₹) | 9.82 | 0.39 | not comparable | 10.48 | −6.3% |
| Net margin (%) | 8.1 | 1.0 | 7.1 |
Consolidated
- Filed with BSE
- 13 Aug 2019, 18:28 IST
- Board meeting
- 13 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Aug 2019, 18:28 IST
- Board meeting
- 13 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE